secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0000950170-24-036822
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology sells royalty rights to Novartis for $8M upfront cash
--------------------------------------------------------------------

- One-time $8M payment from Novartis for rights to Beovu and another asset royalties.
- All prior royalties from Apexigen and Pyxis Oncology are free from reclaim.
- Non-dilutive capital to support lead ADC asset PYX-201 development.
- Pyxis retains rights to three other antibodies from Apexigen licensees.
- $8M payment to be recorded in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024036822/0000950170-24-036822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024036822/pyxs-20240327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer